Methicillin-resistant Staphylococcus aureus and beyond: What's new in the world of the 'golden staph'?

ANZ Journal of Surgery

Volumn 74, Issue 6, 2004, Pages 465-469

  Marshall, Caroline ^a,b   Kossmann, Thomas ^b   Wesselingh, Steve ^c   Spelman, Denis ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

Author keywords

Antibiotic prophylaxis; Bloodstream infection; Hand hygiene; Methicillin resistant Staphylococcus aureus; Mupirocin; Vancomycin resistant Staphylococcus aureus

Indexed keywords

ANTIINFECTIVE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; DISINFECTANT AGENT; GLYCOPEPTIDE; LINEZOLID; METICILLIN; OXAZOLIDINONE DERIVATIVE; PSEUDOMONIC ACID; TEICOPLANIN; VANCOMYCIN;

BACTERIUM ISOLATE; HOSPITAL; HUMAN; HYGIENE; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PLAGUE; POSTOPERATIVE INFECTION; PROPHYLAXIS; REVIEW; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION;

HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 3042798609     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2004.03034.x     Document Type: Review

References (83)

1. Anonymous. A new penicillin. BMJ 1960; 2: 720-1.
2. Jevons MP. 'Celbenin'-resistant staphylococci. BMJ 1961; 1: 124-5.
3. National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 to June 2002, issued August 2002. Am. J. Infect. Control. 2002; 30: 458-75.
4. Vincent J-L, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European prevalence of infection in intensive care (EPIC) study. JAMA 1995; 274: 639-44.
5. PHLS. Surveillance of Hospital-Acquired Bacteraemia in English Hospitals 1997-1999. London: Public Health Laboratory Service, 2000.
6. PHLS. Surveillance of Surgical Site Infection in English Hospitals. London: Public Health Laboratory Service, 2000.
7. McDonald M. The epidemiology of methicillin-resistant Staphylococcus aureus: surgical relevance 20 years on. Aust. NZ J. Surg. 1997; 67: 682-5.
8. Teare EL, Barrett SP. Is it time to stop searching for MRSA? Stop the ritual of tracing colonised people. BMJ 1997; 314: 665-6.
9. Barrett SP, Mummery RV, Chattopadhyay B. Trying to control MRSA causes more problems than it solves. J. Hosp. Infect. 1998; 39: 85-93.
10. McManus AT, Mason AD, McManus WF, Pruitt BA. What's in a name? Is methicillin-resistant Staphylococcus aureus just another S. aureus when treated with vancomycin? Arch. Surg. 1989; 124: 1456-9.
11. Herwaldt LA. Control of methicillin-resistant Staphylococcus aureus in the hospital setting. Am. J. Med. 1999; 106: 11-8S.
12. Wenzel RP, Nettleman MD, Jones RN, Pfaller MA. Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am. J. Med. 1991; 91: 221S-7S.
13. Tam AY-C, Yeung C-Y. The changing pattern of severe neonatal staphylococcal infection: a 10-year study. Aust. Paediatr. J. 1988; 24: 275-8.
14. Haley RW, Hightower AW, Khabbaz RF et al. The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit. Ann. Intern. Med. 1982; 97: 297-308.
15. Diekema DJ, Pfaller MA, Schmitz FJ et al. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-99. Clin. Infect. Dis. 2001; 32: S114-32.
16. Marshall C, Harrington G, Wolfe R, Fairley CK, Wesselingh S, Spelman D. Acquisition of methicillin-resistant Staphylococcus aureus in a large intensive care unit. Infect. Control Hosp. Epidemiol. 2003; 24: 322-6.
17. Collins N, Gosbell IB, Wilson SF. Community-acquired MRSA. bacteraemia. MJA 2002; 177: 55-6.
18. Collignon P, Gosbell I, Vickery A, Nimmo G, Stylianopoulos T, Gottlieb T. Community-acquired methicillin-resistant Staphylococcus aureus in Australia. Lancet 1998; 352: 145.
19. The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect. Control Hosp. Epidemiol. 2002; 23: 106-8.
20. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect. Control Hosp. Epidemiol. 2001; 22: 99-104.
21. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect. Control. Hosp. Epidemiol. 1999; 20: 408-11.
22. Papia G, Louie M, Tralla A, Johnson C, Collins V, Simor AE. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect. Control. Hosp. Epidemiol. 1999; 20: 473-7.
23. Karchmer TB, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 2002; 51: 126-32.
24. Barber M. Methicillin-resistant staphylococci. J. Clin. Path. 1961; 14: 385-93.
25. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin. Infect Dis. 1995; 21: 1217-23.
26. Blot SI, Vandewoude KH, Koste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch. Intern. Med. 2002; 162: 2229-35.
27. Monnet D. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect. Control. Hosp. Epidemiol. 1998; 19: 552-9.
28. Mest DR, Wong DH, Shimoda KJ, Mulligan ME, Wilson SE. Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection. Anesth. Analg. 1994; 78: 644-50.
29. Hershow RC, Khayr WF, Smith NL. A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital. Infect. Control Hosp. Epidemiol. 1992; 13: 587-93.
30. Lentino JR, Hennein H, Krause S et al. A comparison of pneumonia caused by gentamicin, methicillin-resistant and gentamicin, methicillin-sensitive Staphylococcus aureus: epidemiologic and clinical studies. Infect. Control 1985; 6: 267-72.
31. Rezende NA, Blumberg HM, Metzger BS, Larsen NM, Ray SM, McGowan JE Jr Risk factors for methicillin-resistance among patients with Staphylococcus aureus bacteremia at the time of hospital admission. Am. J. Med. Sci. 2002; 323: 117-23.
32. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother. 2002; 49: 999-1005.
33. Dziekan G, Hahn A, Thüne K et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study. J. Hosp. Infect. 2000; 46: 263-70.
34. Sørensen TL, Monnet D. Control of antibiotic use in the community: the Danish experience. Infect. Control. Hosp. Epidemiol. 2000; 21: 387-9.
35. Schentag JJ, Hyatt JM, Carr JR et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin. Infect. Dis. 1998; 26: 1204-14.
36. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2001; 9: 2001.
37. Stone SP, Veric V, Quick A, Balestrini AA, Kibbler C. The effect of an enhanced infection-control policy on the incidence of Clostridium difficile infection and methicillin-resistant Staphylococcus aureus colonization in acute elderly medical patients. Age Ageing 1998; 27: 561-8.
38. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin. Infect. Dis. 1999; 28: 1062-6.
39. Frank MO, Batteiger BE, Sorensen SJ et al. Decrease in expenditures and selected nosocomial infections following implementation on an antimicrobial-prescribing improvement program. Clin. Perf. Qual. Health Care 1997; 5: 180-8.
40. Gul YA, Lian LH, Jabar FM, Moissinac K. Antibiotic prophylaxis in elective colorectal surgery. ANZ J. Surg. 2002; 72: 275-8.
41. McDonald M, Grabsch EA, Marshall C, Forbes A. Single-versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Aust. NZ J. Surg. 1998; 68: 388-96.
42. Gillespie WJ, Walenkamp G. Antibiotic prophylaxis for surgery for proximal femoral and other closed long bone fractures. Cochrane Database Syst Rev. 2002; 2.
43. Barker IIFG. Efficacy of prophylactic antibiotic therapy in spinal surgery: a meta-analysis. Neurosurgery 2002; 51: 391-401.
44. Carrel TP, Eisinger E, Vogt M, Turina MI. Pneumonia after cardiac surgery is predictable by tracheal aspirates but cannot be prevented by prolonged antibiotic prophylaxis. Ann. Thorac. Surg. 2001; 72: 143-8.
45. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation 2000; 101: 2916-21.
46. Schmidt-Matthiesen A, Röding H, Windolf J et al. A prospective, randomised comparison of single- vs. multiple-dose antibiotic prophylaxis in penetrating trauma. Chemotherapy 1999; 45: 380-91.
47. Bozorgzadeh A, Pizzi WF, Barie PS et al. The duration of antibiotic administration in penetrating abdominal trauma. Am. J. Surg. 1999; 177: 125-31.
48. Velmahos GC, Toutouzas KG, Sarkisyan G et al. Severe trauma is not an excuse for prolonged antibiotic prophylaxis. Arch. Surg. 2002; 137: 537-42.
49. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [letter; comment]. Lancet 1998; 351: 1212.
50. Hiramatsu K. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb. Mortal. Wkly Rep. 1997; 46: 624-6.
51. Martin R, Wilcox KR. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb. Mortal. Wkly Rep. 1997; 46: 765-6.
52. Ward PB, Johnson PDR, Grabsch EA, Mayall BC, Grayson ML. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. MJA 2001; 175: 480-3.
53. Miller D, Urdaneta V, Weltman A. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb. Mortal. Wkly Rep. 2002; 51: 902.
54. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb. Mortal. Wkly Rep. 2002; 51: 565-7.
55. Fridkin SK, Hageman J, McDougal LK et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 2003; 36: 429-39.
56. Rubin LG, Tucci V, Cercenado E, Eliopoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect. Control. Hosp. Epidemiol. 1992; 13: 700-5.
57. Handwerger S, Raucher B, Altarac D et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin and gentamicin. Clin. Infect. Dis. 1993; 16: 750-5.
58. Naimi TS, Andersen D, O'Boyle C et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin. Infect. Dis. 2003; 36: 1609-10.
59. Pittet D, Mourouga P, Perneger T. Compliance with handwashing in a teaching hospital. Ann. Intern. Med. 1999; 130: 126-30.
60. Pittet D, Hugonnet S, Harbarth S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000; 356: 1307-12.
61. Gopal Rao G, Jeanes A, Osman M, Aylott C, Green J. Marketing hand hygiene in hospitals - a case study. J. Hosp. Infect. 2002; 50: 42-7.
62. Teare L, Cookson B, Stone S. Hand hygiene. Use alcohol hand rubs between patients: they reduce the transmission of infection. BMJ 2001; 323: 411-12.
63. Boyce JM. Using alcohol for hand antisepsis: dispelling old myths. Infect. Control Hosp. Epidemiol. 2000; 21: 438-41.
64. Pittet D. Promotion of hand hygiene: magic, hype or scientific challenge? Infect. Control Hosp. Epidemiol. 2002; 23: 118-19.
65. Mulberry G, Snyder AT, Heilman J, Pyrek J, Stahl J. Evaluation of a waterless, scrubless chlorhexidine gluconate/ethanol surgical scrub for antimicrobial efficacy. Am. J. Infect. Control 2001; 29: 377-82.
66. Parienti JJ, Thibon P, Heller R et al. Hand-rubbing with an aqueous alcoholic solution vs traditional surgical hand-scrubbing and 30-day surgical site infection rates. A randomized equivalence study. JAMA 2002; 288: 722-7.
67. Centers for Disease Control and Prevention. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/APIC/IDSA Hand Hygiene Task Force. MMWR 2002; 51: 1-44.
68. Kalmeijer MD, Van Nieuwland-Bollen E, Bogaers-Hofman D, De Baere GAJ, Kluytmans JAJW. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect. Control. Hosp. Epidemiol. 2000; 21: 319-23.
69. Bert F, Galdbart J-O, Zarrouk V et al. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin. Infect. Dis. 2000; 31: 1295-9.
70. Kluytmans JAJW, Mouton JW, Ijzerman EPF et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J. Infect. Dis. 1995; 171: 216-19.
71. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 2001; 344: 11-16.
72. Kluytmans JAJW, Mouton JW, VandenBergh MFQ et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect. Control. Hosp. Epidemiol. 1996; 17: 780-5.
73. Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal MM, Edixhoven PJ, Spies-van Rooijen NH. Prophylactic mupirocin could reduce orthopedic wound infections. Acta Orthop. Scand. 1998; 69: 412-14.
74. Cimochowski GE, Harostock MD, Brown R, Bernardi M, Alonzo N, Coyle K. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann. Thorac. Surg. 2001; 71: 1572-9.
75. Yano M, Doki Y, Inoue M, Tsujinaka T, Shiozaki H. Preoperative intranasal mupirocin ointment significantly reduces postoperative infection with Staphylococcus aureus in patients undergoing gastrointestinal surgery. Jpn J. Surg. 2000; 30: 16-21.
76. Wilcox MH, Hall J, Pike H et al. Use of perioperative mupirocin to prevent methicillin-resistant Staphylococcus aureus (MRSA) orthopaedic surgical site infections. J. Hosp. Infect. 2003; 54: 196-201.
77. Paterson DL, Rihs JD, Squier C et al. Lack of efficacy of mupirocin in the prevention of infections with methicillin-resistant Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003; 75: 194-8.
78. Perl TM, Cullen JJ, Wenzel RP et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N. Engl. J. Med. 2002; 346: 1871-7.
79. Kalmeijer MD, Coertjens H, Van Nieuwland-Bollen PM et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin. Infect. Dis. 2002; 35: 353-8.
80. Kauffman CA, Terpenning MS, He X et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin. Am. J. Med. 1993; 94: 371-8.
81. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect. Control. Hosp. Epidemiol. 1996; 17: 811-13.
82. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
83. Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin. Infect. Dis. 2002; 35: 1018-20.